
## Supplementary Figure 1



Supplementary Figure 1: anti-CD69 and Pl3K $\delta$  combination therapy does not alter tumor burden. (A) Schematic diagram shows the experimental protocol: Balb/C mice were treated daily for the duration of the study with either 75mg/kg of Pl-3065 or vehicle by oral gavage and were administered anti-CD69 antibody (100 $\mu$ g) at the days indicated (8 mice/group). (B) Tumor growth curves from mice treated with Pl-3065 or vehicle  $\pm$  anti-CD69. All data is displayed as the mean $\pm$ SEM.